Tech Company Financing Transactions
Degron Therapeutics Funding Round
Degron Therapeutics, based in San Diego, secured $40 million from Lapam Capital, Fortune China Limited and Kinghall Ventures.
Transaction Overview
Company Name
Announced On
5/15/2026
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead program, DEG6498, a first-in-class HuR (Human antigen R) molecular glue degrader, which entered the clinic in late 2025 with first patient dosed in November.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3210 Merryfield Row
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Email Address
Overview
Degron Therapeutics aims to become a global leader in the discovery and development of a new class of targeted protein degradation therapeutics, small molecule molecular glue degrader (MGD) drugs. Degron has assembled a team of world-class executives and scientific leaders, bringing its scientific excellence to the identification and validation of disease targets, particularly those undruggable by conventional small molecule inhibitors, and novel selective MGD compounds to meet unmet medical needs in all therapeutic areas.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lily Zou
Chief Scientific Officer
Yong Cang
Browse more venture capital transactions:
Prev: 5/15/2026: Wirestock venture capital transaction
Next: 5/15/2026: Gridcare venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on funding rounds that are announced publicly. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs